HUTCHMED says AstraZeneca files US NDA for Orpathys-Tagrisso lung cancer combo

By Public Technologies
  • AstraZeneca filed a US FDA NDA for savolitinib with osimertinib in MET-driven EGFR-mutated NSCLC following EGFR-TKI progression.
  • HUTCHMED is a co-developer of savolitinib; the application seeks a biomarker-directed oral regimen for MET overexpression or amplification.
  • Filing relies on the Phase III SAFFRON trial, which met progression-free survival and overall survival endpoints versus platinum-doublet chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609282000PRIMZONEFULLFEED9834957) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk